T lymphocyte subsets in cancer immunity: Friends or foes

Chraa, Dounia; Naim, A.; Olive, Daniel; Badou, Abdallah

doi:10.1002/jlb.mr0318-097r

Cited by 128 publications

(102 citation statements)

References 163 publications

(226 reference statements)

Supporting

Mentioning

102

Contrasting

Order By: Relevance

“…Lymphocytes play a vital role in influencing immune responses to tumors. Whether lymphocytes mount an immune response or a promote immune tolerance toward tumor cells is influenced by a number of factors including, cytokines, tumor cell immunoregulatory molecules, and secreted proteins, as reviewed by Chraa et al (53). In addition many recent advancements in NSCLC therapy act to alter T-cell responses.…”

Section: Leukocytes and C-met Expressionmentioning

confidence: 99%

The Emerging Role of the c-MET-HGF Axis in Non-small Cell Lung Cancer Tumor Immunology and Immunotherapy

et al. 2020

View full text Add to dashboard Cite

Study of the c-Met-HGF axis in non-small cell lung cancer (NSCLC) has focused on the roles of c-MET signaling in neoplastic epithelial cells and the secretion of its ligand hepatocyte growth factor (HGF) by tumor stromal cells. However, there is increasing evidence that some leukocyte subsets also express c-MET raising the possibility of an immunomodulatory role for this axis. Consequently, the role of the c-MET-HGF axis in immunoncology is an active area of ongoing research. This review summarizes current knowledge of c-MET expression in NSCLC, the prognostic significance of these findings and the mechanisms by which the c-MET-HGF axis might act in NSCLC, focusing on the emerging evidence for an immunoregulatory role.

show abstract

Section: Leukocytes and C-met Expressionmentioning

confidence: 99%

The Emerging Role of the c-MET-HGF Axis in Non-small Cell Lung Cancer Tumor Immunology and Immunotherapy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…T lymphocytes play a crucial role in shaping the immune response against cancer. Multiple studies have demonstrated the presence of T lymphocytes in various types of mammary gland neoplasms [19]. A recent study has shown that lymphocytes comprise the primary population of inflammatory cells infiltrating mammary tumors regardless of their histological type [6].…”

Section: Discussionmentioning

confidence: 99%

The Expression of Selected Factors Related to T Lymphocyte Activity in Canine Mammary Tumors

Bujak

Szopa

Pingwara

et al. 2020

IJMS

View full text Add to dashboard Cite

Crosstalk between neoplastic and immune cells in the tumor microenvironment (TME) influences the progression of disease in human and canine cancer patients. Given that canine mammary tumors are a useful model to study breast cancer biology, we aimed to evaluate the expression of genes associated with T lymphocyte activity in benign, malignant, and metastatic canine mammary tumors. Interestingly, metastatic tumors exhibit increased expression of CXCR3, CCR2, IL-4, IL-12p40, and IL-17. In particular, we focused on IL-17, a key interleukin associated with the Th17 lymphocyte phenotype. Th17 cells have been shown to play a contradictory role in tumor immunity. Although IL-17 showed a high expression in the metastatic tumors, the expression of RORγt, a crucial transcription factor for Th17 differentiation was barely detected. We further investigated IL-17 expression using immunohistochemistry, through which we confirmed the increased expression of this interleukin in malignant and metastatic mammary tumors. Finally, we compared the plasma levels of IL-17 in healthy and malignant mammary tumor-bearing dogs using ELISA but found no differences between the groups. Our data indicate that the IL-17 in metastatic tumors may be produced by other cell types, but not by Th17 lymphocytes. Overall, our results broaden the available knowledge on the interactions in canine mammary tumors and provide insight into the development of new therapeutic strategies, with potential benefits for human immune oncology.

show abstract

“…We then compared the frequency profile of Vβ subfamily T cells in AML patients and found relatively high or low frequency of Vβ subfamily CD4+ or CD8+ T cells in AML. It is well known that different T cell subset and Vβ subfamily T cells have different functions based on antigen epitope recognition by different TCRs, indicating skewed proliferation of Vβ subfamily T cells in AML, and such T cell proliferation may be activated by a clonally expanded AML‐associated antigen. These so‐called tumor‐specific cytotoxic T cells may display cytotoxic activity against AML cells .…”

Section: Discussionmentioning

confidence: 99%

A skewed distribution and increased PD-1+Vβ+CD4+/CD8+ T cells in patients with acute myeloid leukemia

Huang

Tan

Chen

et al. 2019

Journal of Leukocyte Biology

View full text Add to dashboard Cite

The limited application of immunotherapy in acute myeloid leukemia (AML) may be due to poor understanding of the global T cell immune dysfunction in AML. In this study, we analyzed the distribution characteristics of 24 TCR Vβ subfamilies in CD3+, CD4+, and CD8+ T cells in AML patients and healthy controls. The percentage of TCR Vβ subfamily T cells was predominately lower in most AML cases, while it was increased in some cases. TCR Vβ2+T cells were increased in AML, particularly TCR Vβ2+CD4+T cells, which were significantly higher. To further address the immunosuppression in different Vβ subfamilies, we characterized the distribution of program death‐1 (PD‐1)+T cells in TCR Vβ subfamilies of CD4+ and CD8+T cells. Significantly higher levels of PD‐1+Vβ+T cells were found for most Vβ subfamilies in most AML cases. A higher percentage of PD‐1+Vβ2+T cells with a high number of Vβ2+T cells was found in all of the CD3+, CD4+, and CD8+ T cell subsets. Moreover, increasing PD‐1+Vβ7.2, Vβ8+, Vβ14+, Vβ16+, and Vβ22+CD8+T cells were distributed in the AML‐M5 subtype group compared with the AML‐M3 group. In addition, higher PD‐1+ Vβ5.2+ and PD‐1+ Vβ12+CD8+T cells were associated with AML patients who had a poor response to chemotherapy. In conclusion, increased PD‐1+Vβ+T cells is a common characteristic of AML, higher PD‐1+Vβ2+T cells may be associated with a low antileukemia effect, and higher PD‐1+Vβ5.2+ and PD‐1+Vβ12+CD8+T cells may be related to poor prognosis in AML. These characteristics may be worth considering as immune biomarkers for clinical outcome in AML.

show abstract

T lymphocyte subsets in cancer immunity: Friends or foes

Cited by 128 publications

References 163 publications

The Emerging Role of the c-MET-HGF Axis in Non-small Cell Lung Cancer Tumor Immunology and Immunotherapy

The Emerging Role of the c-MET-HGF Axis in Non-small Cell Lung Cancer Tumor Immunology and Immunotherapy

The Expression of Selected Factors Related to T Lymphocyte Activity in Canine Mammary Tumors

A skewed distribution and increased PD-1+Vβ+CD4+/CD8+ T cells in patients with acute myeloid leukemia

Contact Info

Product

Resources

About